Pfizer drug shows 40% reduction in breast cancer progression risk
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced that its experimental drug atirmociclib met the primary endpoint in a Phase 2 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


